Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context

Sneha Gullapalli; Jordi Remon; Lizza El Hendriks; Gilberto Lopes

doi:10.2147/OTT.S259308

Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context

Sneha Gullapalli, Jordi Remon^*, Lizza El Hendriks, Gilberto Lopes

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

Abstract

Immune checkpoint inhibitors (ICIs) have transformed the therapeutic strategy and prognosis of advanced non-small cell lung cancer (NSCLC) patients. Nowadays, ICIs as monotherapy or in combination with chemotherapy are the standard of care treatment in advanced NSCLC, and in stage III, durvalumab (a programmed death ligand 1 inhibitor) is the unique drug approved as consolidation treatment after chemo-radiotherapy. This article reviews the pharmacological properties, clinical activity and safety of durvalumab as mono - therapy or in combination with chemotherapy or other ICIs in the therapeutic strategy of NSCLC patients.

Original language	English
Pages (from-to)	6885-6896
Number of pages	12
Journal	Oncotargets and Therapy
Volume	13
DOIs	https://doi.org/10.2147/OTT.S259308
Publication status	Published - 14 Jul 2020

Keywords

durvalumab
non-small cell lung cancer
PACIFIC
rechallenge
MYSTIC
PLATINUM-BASED CHEMOTHERAPY
STAGE-III NSCLC
CHEMORADIOTHERAPY REGIMEN
PHASE-III
PEMBROLIZUMAB
NIVOLUMAB
EFFICACY
OUTCOMES
1ST-LINE
SAFETY

Access to Document

10.2147/OTT.S259308Licence: CC BY-NC

Cite this

@article{596ce281fdb04c78a891f9931d0e26ce,

title = "Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context",

abstract = "Immune checkpoint inhibitors (ICIs) have transformed the therapeutic strategy and prognosis of advanced non-small cell lung cancer (NSCLC) patients. Nowadays, ICIs as monotherapy or in combination with chemotherapy are the standard of care treatment in advanced NSCLC, and in stage III, durvalumab (a programmed death ligand 1 inhibitor) is the unique drug approved as consolidation treatment after chemo-radiotherapy. This article reviews the pharmacological properties, clinical activity and safety of durvalumab as mono - therapy or in combination with chemotherapy or other ICIs in the therapeutic strategy of NSCLC patients.",

keywords = "durvalumab, non-small cell lung cancer, PACIFIC, rechallenge, MYSTIC, PLATINUM-BASED CHEMOTHERAPY, STAGE-III NSCLC, CHEMORADIOTHERAPY REGIMEN, PHASE-III, PEMBROLIZUMAB, NIVOLUMAB, EFFICACY, OUTCOMES, 1ST-LINE, SAFETY",

author = "Sneha Gullapalli and Jordi Remon and {El Hendriks}, Lizza and Gilberto Lopes",

note = "Funding Information: GL reports no conflicts of interest related to the current work; received institutions grants from Merck, Roche Genentech, AstraZeneca, BMS, EMD Serono, Novartis, Tesaro, Blueprint medicines, G1 Therapeutics US NIH/ NCI, Singapore A-Star, Brazil CNPq outside the current work. The authors report no other conflicts of interest in this work. Publisher Copyright: {\textcopyright} 2020 Gullapalli et al.",

year = "2020",

month = jul,

day = "14",

doi = "10.2147/OTT.S259308",

language = "English",

volume = "13",

pages = "6885--6896",

journal = "Oncotargets and Therapy",

issn = "1178-6930",

publisher = "Dove Medical Press Ltd",

}

TY - JOUR

T1 - Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer

T2 - Durvalumab in Context

AU - Gullapalli, Sneha

AU - Remon, Jordi

AU - El Hendriks, Lizza

AU - Lopes, Gilberto

N1 - Funding Information: GL reports no conflicts of interest related to the current work; received institutions grants from Merck, Roche Genentech, AstraZeneca, BMS, EMD Serono, Novartis, Tesaro, Blueprint medicines, G1 Therapeutics US NIH/ NCI, Singapore A-Star, Brazil CNPq outside the current work. The authors report no other conflicts of interest in this work. Publisher Copyright: © 2020 Gullapalli et al.

PY - 2020/7/14

Y1 - 2020/7/14

N2 - Immune checkpoint inhibitors (ICIs) have transformed the therapeutic strategy and prognosis of advanced non-small cell lung cancer (NSCLC) patients. Nowadays, ICIs as monotherapy or in combination with chemotherapy are the standard of care treatment in advanced NSCLC, and in stage III, durvalumab (a programmed death ligand 1 inhibitor) is the unique drug approved as consolidation treatment after chemo-radiotherapy. This article reviews the pharmacological properties, clinical activity and safety of durvalumab as mono - therapy or in combination with chemotherapy or other ICIs in the therapeutic strategy of NSCLC patients.

AB - Immune checkpoint inhibitors (ICIs) have transformed the therapeutic strategy and prognosis of advanced non-small cell lung cancer (NSCLC) patients. Nowadays, ICIs as monotherapy or in combination with chemotherapy are the standard of care treatment in advanced NSCLC, and in stage III, durvalumab (a programmed death ligand 1 inhibitor) is the unique drug approved as consolidation treatment after chemo-radiotherapy. This article reviews the pharmacological properties, clinical activity and safety of durvalumab as mono - therapy or in combination with chemotherapy or other ICIs in the therapeutic strategy of NSCLC patients.

KW - durvalumab

KW - non-small cell lung cancer

KW - PACIFIC

KW - rechallenge

KW - MYSTIC

KW - PLATINUM-BASED CHEMOTHERAPY

KW - STAGE-III NSCLC

KW - CHEMORADIOTHERAPY REGIMEN

KW - PHASE-III

KW - PEMBROLIZUMAB

KW - NIVOLUMAB

KW - EFFICACY

KW - OUTCOMES

KW - 1ST-LINE

KW - SAFETY

U2 - 10.2147/OTT.S259308

DO - 10.2147/OTT.S259308

M3 - (Systematic) Review article

C2 - 32764980

SN - 1178-6930

VL - 13

SP - 6885

EP - 6896

JO - Oncotargets and Therapy

JF - Oncotargets and Therapy

ER -